US20130143237A1 - Compositions and methods for prostate cancer analysis - Google Patents

Compositions and methods for prostate cancer analysis Download PDF

Info

Publication number
US20130143237A1
US20130143237A1 US13/689,407 US201213689407A US2013143237A1 US 20130143237 A1 US20130143237 A1 US 20130143237A1 US 201213689407 A US201213689407 A US 201213689407A US 2013143237 A1 US2013143237 A1 US 2013143237A1
Authority
US
United States
Prior art keywords
antibody
prostate
cancer cells
steap
specific marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/689,407
Other languages
English (en)
Inventor
Siminder Atwal
Jo-Anne Hongo
Mark Lackner
Elizabeth Punnoose
Bonnee Rubinfeld
Rajesh Vij
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to US13/689,407 priority Critical patent/US20130143237A1/en
Publication of US20130143237A1 publication Critical patent/US20130143237A1/en
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PUNNOOSE, ELIZABETH, LACKNER, MARK, VIJ, RAJESH, ATWAL, Siminder, RUBINFELD, BONNEE, HONGO, JO-ANNE
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENENTECH, INC.
Priority to US14/919,388 priority patent/US9632091B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90287—Oxidoreductases (1.) oxidising metal ions (1.16)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
US13/689,407 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis Abandoned US20130143237A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/689,407 US20130143237A1 (en) 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis
US14/919,388 US9632091B2 (en) 2011-11-29 2015-10-21 Compositions and methods for prostate cancer analysis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161629886P 2011-11-29 2011-11-29
US201261703099P 2012-09-19 2012-09-19
US13/689,407 US20130143237A1 (en) 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/919,388 Continuation US9632091B2 (en) 2011-11-29 2015-10-21 Compositions and methods for prostate cancer analysis

Publications (1)

Publication Number Publication Date
US20130143237A1 true US20130143237A1 (en) 2013-06-06

Family

ID=47324459

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/689,407 Abandoned US20130143237A1 (en) 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis
US14/919,388 Active US9632091B2 (en) 2011-11-29 2015-10-21 Compositions and methods for prostate cancer analysis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/919,388 Active US9632091B2 (en) 2011-11-29 2015-10-21 Compositions and methods for prostate cancer analysis

Country Status (15)

Country Link
US (2) US20130143237A1 (ru)
EP (1) EP2786151B1 (ru)
JP (1) JP6219304B2 (ru)
KR (1) KR101951514B1 (ru)
CN (1) CN104067127A (ru)
AR (1) AR089028A1 (ru)
AU (1) AU2012345926A1 (ru)
BR (1) BR112014012882A2 (ru)
CA (1) CA2854042A1 (ru)
IL (1) IL232466A (ru)
MX (1) MX350807B (ru)
RU (1) RU2641968C2 (ru)
SG (1) SG11201402711SA (ru)
WO (1) WO2013082249A2 (ru)
ZA (1) ZA201403110B (ru)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016172160A1 (en) * 2015-04-21 2016-10-27 Genentech, Inc. Compositions and methods for prostate cancer analysis
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
WO2022000065A1 (pt) * 2020-07-02 2022-01-06 Universidade Federal de Uberlândia Aptâmero modificado, sistema aptaimunológico, painel aptaimunológico, kit, método e uso no diagnóstico de câncer de próstata

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646661A (zh) * 2014-03-24 2016-06-08 朱育盼 特异性结合前列腺癌的短肽pcp2及其应用
CN108179134B (zh) * 2017-12-27 2020-11-24 武汉大学 基于EpCAM/PSMA双抗体功能化微流控芯片及其制备方法和应用
SG11202013138RA (en) 2018-07-02 2021-01-28 Amgen Inc Anti-steap1 antigen-binding protein
AU2020343652A1 (en) * 2019-09-05 2022-03-24 Memorial Sloan Kettering Cancer Center Anti-STEAP1 antibodies and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69941689D1 (de) 1998-02-12 2010-01-07 Univ Texas Verfahren und reagenzien zur raschen und effizienten isolierung zirkulierender krebszellen
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
JP4855577B2 (ja) 1998-06-01 2012-01-18 アジェンシス，インコーポレイテッド ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2001025454A2 (en) 1999-10-04 2001-04-12 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2005516217A (ja) * 2001-02-16 2005-06-02 イムニベスト・コーポレイション 循環している癌細胞の急速かつ効果的な単離のための方法および試薬
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
BRPI0418766B8 (pt) * 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP2061814B1 (en) * 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CA2668961A1 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of Michigan Spink1 as a prostate cancer marker and uses thereof
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
WO2010028160A1 (en) 2008-09-05 2010-03-11 The Scripps Research Institute Methods for the detection of circulating tumor cells
EP2558109A4 (en) 2010-04-16 2014-09-24 Bellicum Pharmaceuticals Inc METHOD FOR TREATING HARD TUMORS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Challita-Eid et al (Cancer Res, 2007, 67: 5798-5805) *
Hubert et al (PNAS, 1999, 96(25): 14523-14528) *
Li et al (Zhonghua Nan Ke Xue, 2004, 10(5): 351-354) *
Li et al (Zhonghua Nan Ke Xue, 2004, 10(5): Abstract) *
Riske et al (JBC, 1991, 266(17): 11245-11251) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016172160A1 (en) * 2015-04-21 2016-10-27 Genentech, Inc. Compositions and methods for prostate cancer analysis
US20200200752A1 (en) * 2015-04-21 2020-06-25 Genentech, Inc. Compositions and methods for prostate cancer analysis
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
WO2022000065A1 (pt) * 2020-07-02 2022-01-06 Universidade Federal de Uberlândia Aptâmero modificado, sistema aptaimunológico, painel aptaimunológico, kit, método e uso no diagnóstico de câncer de próstata

Also Published As

Publication number Publication date
AU2012345926A1 (en) 2014-05-29
JP2015507175A (ja) 2015-03-05
CN104067127A (zh) 2014-09-24
RU2014126358A (ru) 2016-01-27
IL232466A (en) 2017-10-31
WO2013082249A3 (en) 2013-10-10
MX350807B (es) 2017-09-20
MX2014006187A (es) 2014-06-23
IL232466A0 (en) 2014-06-30
KR20140100544A (ko) 2014-08-14
CA2854042A1 (en) 2013-06-06
RU2641968C2 (ru) 2018-01-23
US20160274116A1 (en) 2016-09-22
BR112014012882A2 (pt) 2017-06-13
JP6219304B2 (ja) 2017-10-25
EP2786151A2 (en) 2014-10-08
WO2013082249A2 (en) 2013-06-06
EP2786151B1 (en) 2019-07-03
KR101951514B1 (ko) 2019-02-22
US9632091B2 (en) 2017-04-25
AR089028A1 (es) 2014-07-23
ZA201403110B (en) 2017-06-28
SG11201402711SA (en) 2014-06-27

Similar Documents

Publication Publication Date Title
US9632091B2 (en) Compositions and methods for prostate cancer analysis
JP7022191B2 (ja) 前立腺がんの分析のための組成物及び方法
SG186356A1 (en) Novel antibody for the diagnosis and/or prognosis of cancer
EP3094976B1 (en) Cell surface prostate cancer antigen for diagnosis
WO2009090882A1 (ja) 非アルコール性脂肪性肝疾患の診断方法
US11866487B2 (en) Filamin A binding proteins and uses thereof
US20190317097A1 (en) Novel Biomarkers for Sub-Typing Pancreatic Ductal Adenocarcinoma
JP2016500659A5 (ru)
KR101138460B1 (ko) 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
CN111492246A (zh) 用于预测对napi2b靶向疗法的响应的组合物和方法
RU2706967C2 (ru) Антитело к igf-1r и его применение для диагностики рака
KR101439856B1 (ko) 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
JP2022526131A (ja) 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
US20140087400A1 (en) Diagnosis and prognosis of triple negative breast and ovarian cancer
TW201927820A (zh) 抗ｐｄ-ｌ１抗體及使用其來偵測ｐｄ-ｌ１之方法
CN107709362B (zh) Igf-1r抗体及其用于癌症诊断的用途
WO2020225454A1 (en) Detection of fusion protein
JP2010164548A (ja) 非アルコール性脂肪性肝炎を推定するための検出方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENENTECH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ATWAL, SIMINDER;HONGO, JO-ANNE;LACKNER, MARK;AND OTHERS;SIGNING DATES FROM 20130109 TO 20130613;REEL/FRAME:030607/0242

AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENENTECH, INC.;REEL/FRAME:031093/0945

Effective date: 20130709

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION